Cryo-EM structures of the SSTR2 receptor bound to octreotide and paltusotine reveal how these acromegaly drugs selectively activate the receptor and why they produce different signaling profiles.
2 drugs, 1 receptor, different signalsCryo-EM showed octreotide (peptide) and paltusotine (small molecule) activate SSTR2 through distinct binding modes producing different downstream signaling bias
What the researchers found
Cryo-EM analysis of SSTR2-Gi protein complexes revealed the detailed binding modes and activation mechanisms for both octreotide (a peptide analog) and paltusotine (a small molecule). The two drugs show distinct signal bias profiles — meaning they activate different downstream signaling pathways to different degrees despite binding the same receptor.
The structural data explains the molecular basis of subtype selectivity (why these drugs prefer SSTR2 over other somatostatin receptor subtypes) and signal bias (why they trigger some cellular responses more than others). This mechanistic understanding is directly relevant to why a subset of acromegaly patients have poor responses to current somatostatin analogs.
Why it matters
Acromegaly and neuroendocrine tumors are treated with somatostatin analogs, but up to 30% of patients respond poorly. Understanding exactly how these drugs interact with the receptor at the atomic level — and why octreotide and paltusotine produce different signaling patterns — is essential for designing next-generation drugs that work for more patients. This is also the first structural comparison between a peptide drug and a small molecule drug at the same receptor.
The numbers in context
Cryo-EM structures of SSTR2-Gi complexes with octreotide and paltusotine; distinct signal bias profiles; subtype selectivity mechanism resolved
How the study worked
Cryo-electron microscopy analysis of SSTR2-Gi protein complexes bound to octreotide and paltusotine. Pharmacological characterization of signal bias profiles through evaluation of drug-induced receptor activation, G-protein coupling, and downstream signaling. Structural comparison to elucidate mechanisms of ligand recognition, subtype selectivity, and biased signaling.
Who was studied
Not applicable — structural biology study using purified SSTR2-Gi protein complexes
What this study cannot tell us
In vitro structural and pharmacological study only; no patient data or clinical outcomes; static cryo-EM snapshots; purified protein system may not fully reflect in vivo receptor behavior.
How to read the evidence
Published in Nature Communications with high-resolution cryo-EM data, this is strong structural biology evidence. However, it remains in vitro mechanistic work without clinical validation of the signal bias implications, placing it at moderate-preclinical.
When this study was published
Published in 2023, this is recent and timely — paltusotine was in late-stage clinical trials at the time, and this structural work provides molecular context for its mechanism as it approaches potential approval as the first oral acromegaly treatment.
The bigger picture
This research bridges structural biology and drug design for the somatostatin system. With paltusotine being the first oral SSTR2 agonist (potentially replacing injections for acromegaly patients), understanding how it compares to octreotide at the molecular level is timely. The signal bias concept is increasingly recognized as crucial in GPCR pharmacology — the same receptor can be activated in different ways by different drugs, producing different therapeutic outcomes.
Questions still open
- Can the signal bias differences between octreotide and paltusotine explain which acromegaly patients will respond to each drug?
- Could a drug be designed to combine the best signaling properties of both octreotide and paltusotine?
- Do the structural differences extend to other somatostatin receptor subtypes relevant to different tumor types?
Common questions
What is signal bias and why does it matter for acromegaly treatment?
Why is paltusotine significant compared to octreotide?
Read the original research
Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine.
Nature communications, 14(1), 962
Citation
Zhao, Jie; Fu, Hong; Yu, Jingjing; Hong, Weiqi; Tian, Xiaowen; Qi, Jieyu; Sun, Suyue; Zhao, Chang; Wu, Chao; Xu, Zheng; Cheng, Lin; Chai, Renjie; Yan, Wei; Wei, Xiawei; Shao, Zhenhua. (2023). Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine.. Nature communications, 14(1), 962. https://doi.org/10.1038/s41467-023-36673-z